Lumos Diagnostics Holdings Ltd. AI Stock Analysis
Want to see AU:LDX full AI Analyst Report?
Lumos Diagnostics Holdings Ltd. (LDX) AI Stock Analysis
Lumos Diagnostics Holdings Ltd.
(ASX:LDX)
The overall score is heavily pressured by severe profitability challenges, a deeply negative valuation profile, and a pronounced technical downtrend. While the company has significantly improved its balance sheet and achieved positive operating cash flow, its ongoing operational losses and bearish price momentum present substantial investment risks.
Lumos Diagnostics Holdings Ltd. (LDX) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 69.17M
- Dividend Yield
- ―
- Average Volume (3M)
- 1.35M
- Price to Earnings (P/E)
- -7.2
- Beta (1Y)
- 1.94
- Revenue Growth
- 1.36%
- EPS Growth
- 39.13%
- Country
- Australia
- Employees
- 29
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Specialties
Lumos Diagnostics Holdings Ltd. Business Overview & Revenue Model
Company Description
Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. The company’s products include FebriDx, a point-of-care diagnost...
Lumos Diagnostics Holdings Ltd. Earnings Call Summary
The call was broadly positive: management secured a material exclusive U.S. distribution agreement (USD 317M minimum), completed and submitted the CLIA waiver study while expressing near-term optimism about approval, achieved strong product revenue growth and high gross margins, and materially improved cash flow and adjusted EBITDA versus prior years. Key risks remain including an outstanding CLIA waiver approval (which drives the commercial ramp), continued adjusted EBITDA losses, declines in IP/services revenue timing, and the need for incremental manufacturing capacity and near-term financing actions. Overall, the highlights (large distribution deal, reimbursement, margin improvement, improved cash flow, nondilutive funding and product momentum) outweigh the lowlights tied mainly to timing, conditionality of the waiver, and continued operating losses.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management guided that CLIA‑waiver for FebriDx is expected imminently (targeted in March), which would activate the 6‑year U.S. exclusive PHASE distribution deal guaranteeing a minimum USD 317 million in sales to Lumos (PHASE paid a USD 1.0m exclusivity fee in H1 and is expected to prepay USD 5.0m on waiver), and highlighted that FebriDx has Medicare/MAC reimbursement of USD 41.38 per test (seven MACs agreed); BARDA‑funded pediatric work (~USD 6.2m) should add ~20% to the addressable market with the pediatric trial expected to finish by year‑end. Financial guidance reinforced H1 FY26 results: revenue USD 6.1m (products USD 1.7m vs USD 0.8m prior, services USD 4.4m vs USD 5.5m), IP revenue USD 1.0m (vs 2.6m), gross profit USD 4.2m and 68% gross margin, adjusted EBITDA loss USD 1.4m (improved from a USD 4.2m loss in H1 FY24), operating cash flow +USD 0.1m (vs -6.8m), BARDA receipts USD 2.8m, and liquidity support with USD 1.0m drawn on a finance facility (USD 4.0m remaining); management said current manufacturing capacity can meet expected PHASE demand for the first two years but will require investment to scale thereafter.
Lumos Diagnostics Holdings Ltd. Financial Statement Overview
Summary
The company presents a mixed financial profile. While the balance sheet is significantly fortified with reduced debt and positive operating cash flow, it is heavily offset by severe profitability issues, including negative gross margins and widening operating losses.
Income Statement
30NegativeBalance Sheet
75PositiveCash Flow
45Neutral| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.20M | 13.48M | 12.50M | 11.13M | 10.54M | 11.63M |
| Gross Profit | -7.73M | -7.91M | 7.91M | 7.10M | 5.32M | 4.46M |
| EBITDA | -11.59M | -11.84M | -4.73M | -5.33M | -4.87M | ― |
| Net Income | -5.04M | -5.06M | -7.18M | -8.59M | -8.97M | -45.72M |
Balance Sheet | ||||||
| Total Assets | 40.74M | 40.74M | 20.81M | 26.84M | 25.42M | 36.94M |
| Cash, Cash Equivalents and Short-Term Investments | 15.42M | 15.42M | 1.96M | 6.48M | 3.02M | 7.98M |
| Total Debt | 5.94M | 5.94M | 6.99M | 8.06M | 9.79M | 7.19M |
| Total Liabilities | 17.88M | 17.88M | 14.65M | 19.73M | 15.92M | 19.05M |
| Stockholders Equity | 22.85M | 22.85M | 6.16M | 7.11M | 9.50M | 17.89M |
Cash Flow | ||||||
| Free Cash Flow | -1.52M | -1.56M | -9.39M | 848.00K | -9.79M | -22.39M |
| Operating Cash Flow | 970.13K | 1.04M | -9.33M | 946.00K | -9.64M | -18.04M |
| Investing Cash Flow | -2.49M | -2.59M | -53.00K | -98.00K | 4.31M | -4.36M |
| Financing Cash Flow | 14.99M | 15.56M | 5.28M | 2.63M | 652.00K | -10.92M |
Lumos Diagnostics Holdings Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:LDX, the sentiment is Negative. The current price of 0.07 is above the 20-day moving average (MA) of 0.07, below the 50-day MA of 0.09, and below the 200-day MA of 0.14, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 39.75 is Neutral, neither overbought nor oversold. The STOCH value of 60.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:LDX.
Lumos Diagnostics Holdings Ltd. Peers Comparison
Overall Rating
AU:SHL72Outperform
AU:ACL54Neutral
AU:LDX44Neutral
AU:GSS43Neutral
AU:BDX39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 72Outperform | AUD 9.83B | 16.14 | 7.20% | 5.43% | 14.40% | 15.11% | |
| 54Neutral | AUD 624.84M | 27.14 | 15.80% | 3.88% | -0.90% | -25.09% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 44Neutral | AUD 69.17M | -7.18 | -35.89% | ― | 1.36% | 39.13% | |
| 43Neutral | AUD 16.35M | -1.17 | -35.10% | ― | -9.10% | 31.75% | |
| 39Underperform | AUD 22.20M | -2.98 | -881.94% | ― | 743.51% | -1.52% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:LDX | Lumos Diagnostics Holdings Ltd. | 0.07 | -0.10 | -60.00% | |
| AU:BDX | BCAL Diagnostics Limited | 0.06 | -0.02 | -25.00% | |
| AU:GSS | Genetic Signatures Ltd. | 0.07 | -0.22 | -75.17% | |
| AU:SHL | Sonic Healthcare Limited | 19.89 | 0.05 | 0.28% | |
| AU:ACL | Australian Clinical Labs Ltd | 3.35 | 0.88 | 35.63% |
Lumos Diagnostics Holdings Ltd. Corporate Events
Lumos Diagnostics Reports 2026 AGM Voting Results
Lumos Diagnostics Holdings Limited reported the voting results of its 2026 annual general meeting held on 13 November 2026. All 10 ordinary and special resolutions were carried, including adoption of the remuneration report, director elections, equit...
Lumos Reports FebriDx CLIA Waiver and U.S. Site Expansion
Lumos Diagnostics develops rapid, point-of-care diagnostic technologies, including proprietary tests for infectious and inflammatory diseases, digital reader platforms, and assay development and manufacturing services. The company said FDA CLIA waive...
Lumos Diagnostics Outlines Q1 FY27 Update with Strong Investor Disclaimers
Lumos Diagnostics Holdings Ltd. has released its Q1 FY27 results and commercial update via an investor webinar, reiterating its role as a listed medical diagnostics company providing rapid point-of-care testing solutions to healthcare markets. The up...
Lumos Diagnostics Boosts FebriDx Sales as U.S. Rollout Accelerates
Lumos Diagnostics reported first-quarter FY27 revenue of about US$2.0 million, down 39 per cent year on year amid lower services income and the absence of a prior one‑off exclusivity fee, but product revenue surged 224 per cent, led by a 351 per cent...
Lumos Diagnostics Seeks ASX Quotation for 16.5 Million New Shares
Lumos Diagnostics Holdings Ltd. has applied for quotation of 16,500,000 new fully paid ordinary shares on the ASX, with the securities issued on 19 October 2026. The move enlarges the company’s listed share base, signalling an expansion of its capita...
Lumos Diagnostics Sets Q1 FY27 Results Release and Investor Webinar
Lumos Diagnostics Holdings Ltd has scheduled the release of its financial results for the quarter ended 30 September 2026 on 27 October 2026, underscoring continued transparency with investors as it enters FY27. On the same day, the company will host...
Lumos Diagnostics Discloses Final Director Interest as Mehren Departs Board
Lumos Diagnostics Holdings Ltd has reported a change in its board composition, with director Lawrence Mehren ceasing to serve on the board as of 12 October 2026. The company disclosed that Mehren holds 80,000 fully paid ordinary shares as a registere...
Lumos Diagnostics Appoints New Director With No Current Shareholding
Lumos Diagnostics Holdings Ltd has notified the ASX of the appointment of Aizaz Syed as a director effective 12 October 2026. The disclosure was made under listing rule 3.19A.1 and relevant sections of the Corporations Act, highlighting the company’s...
Lumos Diagnostics Sets 2026 AGM as Fully Virtual Event
Lumos Diagnostics Holdings Ltd. has called its Annual General Meeting for 13 November 2026, to be conducted virtually via a Zoom webinar, reflecting its continued use of technology to engage a geographically dispersed shareholder base. The board has...
Lumos Diagnostics Reshapes Board as Major Shareholder Gains Representation
Lumos Diagnostics has appointed Aizaz Syed as a Non-Executive Director, representing its largest shareholder Tenmile Ventures Pty Ltd., as part of changes to its board. Syed brings extensive healthcare investing and corporate strategy experience, ref...
Lumos Diagnostics Options Lapse, Simplifying Capital Structure
Lumos Diagnostics has notified the market of the cessation of several classes of options, including series expiring in August 2026 and December 2027, after they lapsed without being exercised or were otherwise terminated. The expiry of these options...
Lumos Diagnostics Issues New Shares on Employee Option Exercise, Confirms Compliance
Lumos Diagnostics Holdings Ltd., based in Melbourne, operates in the point-of-care diagnostics industry, providing rapid and cost-effective test technology for healthcare professionals. It develops and manufactures customised assays, proprietary digi...
Lumos Diagnostics Issues New Shares After Ryder Capital Option Exercise
Lumos Diagnostics has issued 26,098,017 fully paid ordinary shares following the exercise of an equivalent number of unquoted options by Ryder Capital Ltd, expanding its share capital without a traditional disclosure document. The company affirmed it...
Lumos Diagnostics Seeks ASX Quotation for 26 Million New Shares
Lumos Diagnostics Holdings Ltd. has applied for quotation of 26,098,017 new ordinary fully paid shares on the Australian Securities Exchange, effective September 15, 2026. The move expands the company’s quoted share base and may influence its capital...
Lumos accelerates U.S. FebriDx rollout across major urgent care networks
Lumos Diagnostics is accelerating the U.S. rollout of its FebriDx point-of-care test, expanding live sites to 215 across 26 states and increasing actively evaluated sites to 405 within priority urgent care groups. The company is executing a structure...
Lumos Diagnostics Issues New Shares on Employee Option Exercises and Confirms Regulatory Compliance
Lumos Diagnostics has issued a total of 303,474 fully paid ordinary shares following the exercise of unquoted employee options, including 76,480 shares from options exercised at $0.0576 and 226,994 shares from a cashless option exercise. The company...
Lumos Diagnostics Seeks Quotation for Additional ASX Shares
Lumos Diagnostics Holdings Ltd. has applied for quotation of 303,474 new ordinary fully paid shares on the ASX, with an issue date of 31 August 2026. The additional securities, arising from the exercise or conversion of existing instruments, modestly...
Lumos Director Doug Ward Increases On‑Market Shareholding
Lumos Diagnostics has reported a change in the holdings of director Doug Ward, who increased his stake in the company through an on‑market purchase. Ward acquired 202,131 fully paid ordinary shares for approximately $21,224, lifting his direct shareh...
Lumos Diagnostics Files 2026 Corporate Governance Statement with ASX
Lumos Diagnostics Holdings Limited has lodged its corporate governance statement for the financial year ended 30 June 2026 with the ASX and made it available via its investor website. The statement outlines the extent to which the company complies wi...
Lumos Diagnostics’ FY26 Milestones Expand FebriDx U.S. Market to Over US$1 Billion
Lumos reported a landmark FY26 marked by major regulatory and commercial milestones that significantly expand the U.S. opportunity for its FebriDx test. The company secured an exclusive six-year U.S. distribution agreement with PHASE Scientific value...
Lumos Diagnostics Highlights Point-of-Care Innovation in 2026 Annual Report
Lumos Diagnostics’ 2026 annual report underscores its commitment to innovation in point-of-care testing, highlighting its role in delivering real-time diagnostic information at the patient’s location. By emphasizing world-leading technologies and rap...
Lumos Diagnostics Narrows Annual Loss as Revenue Grows but Going-Concern Risks Persist
Lumos Diagnostics Holdings Limited reported a 6.4% increase in revenue to US$13.19 million for the year ended 30 June 2026, signaling modest growth in its diagnostics business. The company’s net tangible assets per ordinary security improved from neg...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 29, 2026
